Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H12N2O2.ClH |
Molecular Weight | 240.686 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C1CN=C(N1)[C@H]2COC3=CC=CC=C3O2
InChI
InChIKey=MYUBYOVCLMEAOH-HNCPQSOCSA-N
InChI=1S/C11H12N2O2.ClH/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11;/h1-4,10H,5-7H2,(H,12,13);1H/t10-;/m1./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C11H12N2O2 |
Molecular Weight | 204.2252 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Idazoxan is an alpha2 receptor antagonist which also shows activity at imidazoline I1 and I2 receptors and modulates the release of dopamine. Idazoxan was in phase II development in the US. Later the development of idazoxan for schizophrenia was discontinued. It was also in clinical trials for cognition disorders in United Kingdom, and was also discontinued. Idazoxan is used in scientific research as a tool for the study of alpha 2-adrenoceptors. Idazoxan`s diastereoisomers possess different relative selectivity for
alpha2- pre- and postsynaptic receptors: ( )-idazoxan was 7-8 times more potent than (-)-idazoxan in inhibiting p-[3H]aminoclonidine binding, and 40 times more active in antagonizing clonidine at presynaptic level, indicating a better selectivity for alpha2-presynaptic sites. The pre- and postsynaptic alpha2-adrenoceptors have a different affinity for the two enantiomers of idazoxan. Although the stereoisomers are closely related structurally, ( )-idazoxan possesses a stronger affinity for presynaptic sites. This stereoselectivity was less evident for postsynaptic sites. In rats and dogs, both enantiomers antagonized the sympathoinhibitory effects of clonidine. In rats, ( )- idazoxan was 4-7 times more potent than (-)- idazoxan and 3-8 times more than (-)- idazoxan in dogs. A same order of potency was observed
against the sedative effects of clonidine and azepexole in chicks, ( )- idazoxan being 8 times more potent than (-)- idazoxan. Although ( )- idazoxan was more potent than (-) idazoxan, binding studies revealed (-)- idazoxan to be more selective than ( )- idazoxan at central sites. It is concluded that ( )- idazoxan antagonizes both alpha-1 and alpha-2 adrenoceptors and (-)- idazoxan is selective for alpha-2 adrenoceptors. ( )- idazoxan is equipotent for antagonizing postsynaptic alpha-I and alpha-2 adrenoceptors. It is
also a potent alpha-2 antagonist at presynaptic and central
sites and is 4-8 times more potent than (-)- idazoxan but less
selective.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.2 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
(S)-IDAZOXAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
(S)-IDAZOXAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.8 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
(S)-IDAZOXAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
(Imidazolinyl-2)-2-benzodioxane 1-4 (idazoxan) and its stereoisomers, new alpha 2-antagonists. | 1985 |
|
Pharmacological properties of the enantiomers of idazoxan: possible separation between their alpha-adrenoceptor blocking effects. | 1986 |
|
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. | 1986 Oct |
|
Alpha 2-adrenoceptor blocking properties of idazoxan stereoisomers: stereoselectivity for presynaptic alpha 2-adrenoceptors. | 1988 Apr 12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.google.ch/patents/US7595335
Curator's Comment: I.V. route: in rats each enantiomer of idazoxan (( )-idazoxan and (-)-idazoxan) was injected i.v. in cumulative doses (0.01-10 mg/kg) after stabilization of blood pressure and heart rats. Injections were performed every 2 min. https://www.ncbi.nlm.nih.gov/pubmed/2873908
Young healthy male subjects were allocated at random to receive a single dose of each of the following substances on one occasion: 20 mg of idazoxan racemate (polymorph of form I); 10 mg of the R(−) enantiomer; 10 mg of the S( ) enantiomer.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2837681
Binding studies were performed on rat hypothalamic and cortical membranes with p-[3H]aminoclonidine as a selective alpha2-adrenoceptor radioligand. The specific binding of p-[3H]aminoclonidine (2.5 nM) was examined in the presence of increasing concentrations (from 0.03 nM to 1 uM) of idazoxan stereoisomers. (+)-idazoxan (Ki = 2.4 nM) was 7-8 times more potent than (-)- idazoxan (Ki= 18.7 nM) in inhibiting postsynaptic alpha2-adrenoceptors. Competition binding experiments with the two enantiomers were also performed on alpha1-adrenoceptors using [3H]WB4101 as radioligand ((+)-idazoxan Ki=275 nM; (-)-idazoxan Ki =425 nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:23:53 GMT 2023
by
admin
on
Sat Dec 16 09:23:53 GMT 2023
|
Record UNII |
DUA4F30QF8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
72941621
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
PRIMARY | |||
|
89141-62-8
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
PRIMARY | |||
|
DUA4F30QF8
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER |